T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size and complexity of T cell repertoires and the challenges of working with primary T cells. Here we present a high-throughput method to identify TCRs with high functional avidity from diverse human T cell repertoires. The approach used massively parallel microfluidics to generate libraries of natively paired, full-length TCRαβ clones, from millions of primary T cells, which were then expressed in Jurkat cells. The TCRαβ–Jurkat libraries enabled repeated screening and panning for antigen-reactive TCRs using peptide major histocompatibility complex binding and cellular activation. We captured more than 2.9 million natively paired TCRαβ clonotypes from six healthy human donors and identified rare (<0.001% frequency) viral-antigen-reactive TCRs. We also mined a tumor-infiltrating lymphocyte sample from a patient with melanoma and identified several tumor-specific TCRs, which, after expression in primary T cells, led to tumor cell killing.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 17 May 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Yee, C. Adoptive T cell therapy: points to consider. Curr. Opin. Immunol. 51, 197–203 (2018).
Barrett, A. J., Prockop, S. & Bollard, C. M. Virus-specific T cells: broadening applicability. Biol. Blood Marrow Transplant. 24, 13–18 (2018).
Romano, M., Fanelli, G., Albany, C. J., Giganti, G. & Lombardi, G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front. Immunol. 10, 43 (2019).
Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20, 2457–2465 (2014).
Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015).
Tendeiro Rego, R., Morris, E. C. & Lowdell, M. W. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. Cytotherapy 21, 341–357 (2019).
Zhang, J. & Wang, L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol. Cancer Res. Treat. 18, 1533033819831068 (2019).
Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017).
Dawson, N. A. J. & Levings, M. K. Antigen-specific regulatory T cells: are police CARs the answer? Transl. Res. 187, 53–58 (2017).
Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534–1541 (2013).
Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019).
Yossef, R. et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 3, 122467 (2018).
Hu, Z. et al. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood 132, 1911–1921 (2018).
Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349–354 (2005).
Wagner, E. K. et al. Human cytomegalovirus-specific T cell receptor engineered for high affinity and soluble expression using mammalian cell display. J. Biol. Chem. 294, 5790–5804 (2019).
Border, E. C., Sanderson, J. P., Weissensteiner, T., Gerry, A. B. & Pumphrey, N. J. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. Oncoimmunology 8, e1532759 (2019).
Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863–871 (2015).
Guo, X.-Z. J. et al. Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis. Mol. Ther. Methods Clin. Dev. 3, 15054 (2016).
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 (2018).
Adler, A. S. et al. Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. mAbs 9, 1282–1296 (2017).
Wang, B. et al. Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nat. Biotechnol. 36, 152–155 (2018).
Kieke, M. C. et al. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl Acad. Sci. USA 96, 5651–5656 (1999).
Smith, S. N., Harris, D. T. & Kranz, D. M. in Yeast Surface Display 1319, 95–141 (Springer, 2015).
Kuhns, M. S., Davis, M. M. & Garcia, K. C. Deconstructing the form and function of the TCR/CD3 complex. Immunity 24, 133–139 (2006).
Tsuji, T. et al. Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy. Cancer Immunol. Res. 6, 594–604 (2018).
Shugay, M. et al. Towards error-free profiling of immune repertoires. Nat. Methods 11, 653–655 (2014).
Heather, J. M., Ismail, M., Oakes, T. & Chain, B. High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities. Brief. Bioinformatics 19, 554–565 (2018).
Exley, M., Porcelli, S., Furman, M., Garcia, J. & Balk, S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor α chains. J. Exp. Med. 188, 867–876 (1998).
Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012).
Gold, M. C. et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J. Exp. Med. 211, 1601–1610 (2014).
Dellabona, P., Padovan, E., Casorati, G., Brockhaus, M. & Lanzavecchia, A. An invariant Vα24–JαQ/Vβ11 T cell receptor is expressed in all individuals by clonally expanded CD4-8− T cells. J. Exp. Med. 180, 1171–1176 (1994).
Porcelli, S., Yockey, C. E., Brenner, M. B. & Balk, S. P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8− α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCRα chain. J. Exp. Med. 178, 1–16 (1993).
Held, K., Beltrán, E., Moser, M., Hohlfeld, R. & Dornmair, K. T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis. Hum. Immunol. 76, 607–614 (2015).
Dash, P. et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature 547, 89–93 (2017).
Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94–98 (2017).
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
Cole, D. K. et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J. Biol. Chem. 284, 27281–27289 (2009).
Trautmann, L. et al. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175, 6123–6132 (2005).
Day, E. K. et al. Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J. Immunol. 179, 3203–3213 (2007).
Yang, X. et al. Structural basis for clonal diversity of the public T cell response to a dominant human cytomegalovirus epitope. J. Biol. Chem. 290, 29106–29119 (2015).
Sibener, L. V. et al. Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide–MHC binding. Cell 174, 672–687.e27 (2018).
Birnbaum, M. E. et al. Deconstructing the peptide–MHC specificity of T cell recognition. Cell 157, 1073–1087 (2014).
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
Shugay, M. et al. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res. 46, D419–D427 (2018).
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
Gerdemann, U. et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol. Ther. 20, 1622–1632 (2012).
Barrett, A. J. & Bollard, C. M. The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Ann. Transl. Med. 3, 62 (2015).
O’Leary, M. C. et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin. Cancer Res. 25, 1142–1146 (2019).
Bouchkouj, N. et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702–1708 (2019).
Edgar, R. C. & Flyvbjerg, H. Error filtering, pair assembly and error correction for next-generation sequencing reads. Bioinformatics 31, 3476–3482 (2015).
Lefranc, M.-P. et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 37, D1006–D1012 (2009).
Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
Exley, M., Garcia, J., Balk, S. P. & Porcelli, S. Requirements for CD1d recognition by human invariant Vα24+ CD4-CD8− T cells. J. Exp. Med. 186, 109–120 (1997).
Han, M. et al. Invariant or highly conserved TCRα are expressed on double-negative (CD3+CD4−CD8−) and CD8+ T cells. J Immunol 163, 301–311 (1999).
Démoulins, T., Gachelin, G., Bequet, D. & Dormont, D. A biased Vα24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol. Lett. 90, 223–228 (2003).
Greenaway, H. Y. et al. NKT and MAIT invariant TCRα sequences can be produced efficiently by VJ gene recombination. Immunobiology 218, 213–224 (2013).
Van Rhijn, I. et al. A conserved human T cell population targets mycobacterial antigens presented by CD1β. Nat. Immunol. 14, 706–713 (2013).
Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat. Commun. 5, 3866 (2014).
Funston, G. M., Kallioinen, S. E., de Felipe, P., Ryan, M. D. & Iggo, R. D. Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J. Gen. Virol. 89, 389–396 (2008).
Lyons, G. E. et al. Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Cancer Res. 66, 11455–11461 (2006).
Thakral, D., Dobbins, J., Devine, L. & Kavathas, P. B. Differential expression of the human CD8β splice variants and regulation of the M-2 isoform by ubiquitination. J. Immunol. 180, 7431–7442 (2008).
Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873–9880 (1998).
Han, A., Glanville, J., Hansmann, L. & Davis, M. M. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 32, 684–692 (2014).
Chheda, Z. S. et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J. Exp. Med. 215, 141–157 (2018).
Goff, S. L. et al. Enhanced receptor expression and in vitro effector function of a murine–human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol. Immunother. 59, 1551–1560 (2010).
This work was partially funded by National Institute of Allergy and Infectious Diseases grant R43AI120313-01 to D.S.J. and National Cancer Institute grant R43CA232942 to M.J.S. N.O. is supported with funding from the Medical Research Council, Engineering and Physical Sciences Research Council Centre for Doctoral Training (EP/L014904/1). R. Mizrahi, M. Adams, R. Leong and J. Leong (GigaGen) assisted with the development of Gibson assembly protocols. E. Stone and S. Keating (GigaGen) provided useful discussions about general T cell immunology. R. Guest (Immetacyte) provided assistance with isolation and expansion of TILs.
M.J.S., A.L.N., E.K.W., A.S.A., M.A.A., Y.W.L., R.C.E. and D.S.J. are salaried employees of GigaGen, which is an affiliate of GigaMune. GigaMune pays cash to GigaGen for research services. M.J.S., A.L.N., E.K.W., A.S.A., M.A.A., R.C.E., Y.W.L., E.H.M., M.C. and D.S.J. are holders of equity shares in GigaMune. J.M.H. and M.C. hold research positions at the Massachusetts General Hospital. Massachusetts General Hospital has entered into a research collaboration with GigaMune. M.C. is currently an employee of AstraZeneca. M.C. owns equity in Revitope Oncology and Gritstone Oncology. M.C. received consultant fees from Merck Laboratories. J.S.B. and R.E.H. are salaried employees of Immetacyte. R.E.H. is a holder of equity shares in Immetacyte. The viral TCRs and TCR repertoire mining methods are described in US Patent and Trademark Office (USPTO) provisional patent application 62/821808, assigned to GigaMune (M.J.S., A.L.N., E.K.W., Y.W.L., A.S.A., M.A.A. and D.S.J.). The PMEL TCRs are described in USPTO provisional patent application 62/842691, assigned to GigaMune (M.J.S., A.S.A., M.A.A. and D.S.J.). Methods for generating TCR libraries are described in patents WO2012083225A2, US20160362470A1, US20170247684A1 and US20170247683A1, assigned to GigaGen or GigaMune (M.J.S., A.S.A., E.H.M. and D.S.J.).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Figs. 1–41.
Summary of HLA types, CMV and EBV status, number of input cells, number of sequencing reads and number of clonotypes for each of the seven libraries.
Summary of sequencing data for primary T cells, linked TCR libraries, cloned TCR libraries and Jurkat TCR libraries for each of the seven libraries generated in the study.
Summary of the MHC dextramers used in the Jurkat panning experiments.
CDR3, V-gene and J-gene sequences for each TCR identified in the Jurkat panning experiments, plus their frequencies in the initial primary T cell sequencing data.
CDR3, V-gene and J-gene sequences for each TCR identified in the Jurkat panning experiments, plus their frequencies in the initial primary T cell sequencing data and at each step of the Jurkat panning experiments. Also included are MHC dextramer-binding and Jurkat activation validation data for monoclonal TCR constructs.
About this article
Cite this article
Spindler, M.J., Nelson, A.L., Wagner, E.K. et al. Massively parallel interrogation and mining of natively paired human TCRαβ repertoires. Nat Biotechnol 38, 609–619 (2020). https://doi.org/10.1038/s41587-020-0438-y
This article is cited by
Scientific Reports (2023)
Nature Methods (2022)
Nature Cancer (2021)
Nature Biotechnology (2021)